Laboratory of Precision and Nanomedicine develops smart cancer therapeutics with increased potency and decreased side effects.

Our mission is to change the perception of cancer as being a largely incurable disease. We use in vivo peptide phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biologicals, and nanoparticles into tumors to increase their therapeutic index. We focus on development of novel diagnostic tests and therapeutics for the early detection and precision treatment of solid tumors (glioblastoma, and breast, prostate ovarian, prostate, and colorectal carcinoma). Our lab is also at the forefront of development of next generation peptidic shuttles capable of efficient and high capacity payload delivery across the blood brain barrier.

News

EMBO

ERC

wellcome trust

  

 

Recent publications

Images